Mode
Text Size
Log in / Sign up

Early age onset predicts MACE in pediatric cardiomyopathy patients with TTN variantsStudy finds early age of onset predicts heart events in children with TTN gene cardiomyopathy

AI-generated summary of the cited source, checked by automated accuracy review. How we work

Key Takeaway
Consider early age onset as a predictor for MACE in pediatric cardiomyopathy with TTN variants, but recognize study limitations.

This retrospective observational cohort study examined 53 pediatric patients with cardiomyopathy and TTN variants confirmed by whole-exome sequencing. The study assessed the relationship between TTN variants and clinical outcomes, with major adverse cardiovascular events (MACE) as the primary outcome. Secondary outcomes included recurrent heart failure, presence of late gadolinium enhancement on MRI, and the association of combined pathogenic variants with outcomes.

Early age-onset disease served as a predictor for MACE, with a hazard ratio of 1.008 (95% CI=1.000–1.016, p=0.037). An optimal cutoff value for age predicting MACE was identified at 75.50 months, with specificity of 57.1% and sensitivity of 75.0%. In patients with dilated cardiomyopathy specifically, the presence of multiple genetic variants with TTN was associated with more severe adverse outcomes. The study failed to establish an association between combined genetic disorders and worse outcomes in the general cohort.

Safety and tolerability data were not reported. Key limitations include the retrospective design and small sample size of 53 patients. As an observational study, these findings show association rather than causation. The single-center retrospective design limits generalizability, and the precision of effect estimates should be interpreted cautiously. Practice relevance was not explicitly reported, and clinicians should consider these findings preliminary until validated in larger, prospective studies.

Researchers looked back at medical records to understand how TTN gene variants affect children with cardiomyopathy, a disease of the heart muscle. They studied 53 pediatric patients who had both cardiomyopathy and a confirmed TTN variant. The main goal was to see if certain factors could predict major heart problems, like heart failure or severe heart rhythm issues.

The study found that children who developed cardiomyopathy at a younger age were more likely to experience these major heart events. Specifically, an age of onset younger than about 6 years (75.5 months) was identified as a potential warning sign. In children with a type of cardiomyopathy called dilated cardiomyopathy (DCM), having multiple genetic variants in addition to the TTN variant was linked to more severe outcomes.

It is very important to understand what this study does not tell us. This was a small, retrospective study that only looked at associations—it cannot prove that a younger age or extra gene variants cause worse outcomes. The results are from a single group of 53 patients, so they may not apply to all children with this condition. This research is an early step in understanding these complex diseases, and more studies with more patients are needed to confirm the findings.

What this means for you:
Early research links younger age at diagnosis to heart events in kids with TTN cardiomyopathy, but more study is needed.

Study Details

Study typeCohort
EvidenceLevel 3
PublishedApr 2026
View Original Abstract ↓
BackgroundTitin (TTN) variants have been implicated in various types of cardiomyopathy. Allelic variant heterogeneity results in variable clinical phenotypes, which remains a major barrier for effective disease management. We aim to investigate the relationship between TTN variants and their associated cardiomyopathies and clinical outcomes.MethodsA retrospective observational study was performed to evaluate patients with cardiomyopathy and TTN variants confirmed by whole-exome sequencing (WES) from January 2015 to December 2024. Univariable Cox regression analysis was conducted to identify independent risk factors for major adverse cardiovascular events (MACEs), and receiver operating characteristic analysis was used to determine its capability. In addition, the contribution of combined pathogenic variants with the TTN gene was assessed.ResultsA total of 53 patients were identified with TTN variants, with a median onset age of 42.3 months (IQR 18.5–76.1), while 48 of 53 (90.50%) individuals had other genetic variants. Among them, 47.17% of patients presented with recurrent heart failure, while late gadolinium enhancement (LGE) was identified in 56.67% of cases that underwent magnetic resonance imaging (MRI) assessment. The variants in the A-band of TTN were most frequently recorded among the patients. Notably, early age-onset disease (HR = 1.008; 95% CI = 1.000–1.016; p = 0.037) served as a predictor of MACE in pediatrics with TTN-associated cardiomyopathy, and the optimal cutoff value was calculated as 75.50 months (specificity 57.1% and sensitivity 75.0%). Unfortunately, the combined genetic disorders failed to establish an association with worse outcomes in the general cohort. However, the presence of multiple genetic variants was associated with more severe adverse outcomes specifically in patients with dilated cardiomyopathy (DCM), with a higher prevalence of MACE occurrence.ConclusionIn our cohort, early age-onset disease was a predictor of MACE in pediatrics with TTN-associated cardiomyopathy. In addition, the early age of disease onset revealed a higher likelihood of MACE in the first year after diagnosis. Multiple genetic variants with TTN presented more severe adverse outcomes in DCM assessment.
Free Newsletter

Clinical research that matters. Delivered to your inbox.

Join thousands of clinicians and researchers. No spam, unsubscribe anytime.